None listed
Conditions
Brief summary
The purpose of the study is to compare the effects of traditional homeopathic treatment, a generic homeopathic treatment with placebo on symptoms of osteoarthritis of the hip and/or knee.
Interventions
Homeopathic simplex
This preparation is individually prescribed after homeopathic interview. This could be any of the homeopathic medications (200C potency) manufactured by Brauer Natural Medicine.
Sublingual administration on Day 1 of the 4-week treatment period.
2. Homeopathic complex
The composition of the complex is a mixture comprising Actaea spicata 3X (Baneberry), Causticum 12X (Hydrated Lime), Rhus toxicodendron 12X (Poison oak), Kalmia latifolia 5C (Mountain laurel), Bryonia 6C (Wild
Homeopathic simplex This preparation is individually prescribed after homeopathic interview. This could be any of the homeopathic medications (200C potency) manufactured by Brauer Natural Medicine. Sublingual administration on Day 1 of the 4-week treatment period. 2. Homeopathic complex The composition of the complex is a mixture comprising Actaea spicata 3X (Baneberry), Causticum 12X (Hydrated Lime), Rhus toxicodendron 12X (Poison oak), Kalmia latifolia 5C (Mountain laurel), Bryonia 6C (Wild Hops), Colocynthis 6C (Bitter Cucumber), Dulcamara 6C (Deadly Nightshade), Ruta Graveolens 6C (Rue), Kali Carbonicum 6C (Potassium carbonate), Cimicifuga racemosa 9C (Black Cohosh). Administration is 2 pumps sublinguallly tds for the 4-week treatment period.
Sponsors
Australian Centre for Complementary Medicine Education and Research
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Subjects with a diagnosis of osteoarthritis (OA) of the hip or knee, with or without other joint involvement, as defined by:-hip/knee pain while standing, walking and/or in motion of at least 3 months duration, and-evidence of one or more of the following features in an X-ray picture: osteophytes, osteosclerosis, cysts, or joint space narrowing, and-a total WOMAC score of 30 or more at study commencement.Subjects willing to discontinue their current OA treatment for the duration of the study, commencing at least 4 weeks prior to their first visit. This includes treatment with intra-articular injections, corticosteroids, NSAIDs, non-prescription therapies, chondroprotective agents, occlusive dressings, physiotherapy, or orthopaedic technical measures.Subjects who have given their written informed consent.Female subjects of childbearing age who agree to continue using contraceptive measures for the duration of the study.
Exclusion criteria
Severe false alignment of the axis of the knee or hip.Surgery of the knee or hip within the past 2 months or arthroscopy within the past 2 months.Administration of intra-articular injections (e.g. corticosteroids, chondroprotective agents) or treatment with any long acting osteoarthritic therapy within one month of the study commencement.Subjects who use lipolytic, fibrinolytic, anti-coagulent or anti-inflammatory agents or agents that influence platelet function (especially aspirin, aspirin-containing compounds and other NSAIDs) or complementary natural antiarthrotic agents. Infectious, inflammatory rheumatic diseases (e.g. Ross River Fever, rheumatoid arthritis).Female subjects who are pregnant or lactating.Subjects who are unwilling to comply with the study.Subjects with contra-indications to the study medication.Subjects with any condition that, in the opinion of the investigators, might interfere with the evaluation of the study objective.
Outcome results
None listed